Opendata, web and dolomites

EXACT-dna SIGNED

EXtended Analysis of Circulating Tumour DNA to improve cancer management strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EXACT-dna project word cloud

Explore the words cloud of the EXACT-dna project. It provides you a very rough idea of what is the project "EXACT-dna" about.

generating    blood    lower    commercially    ibsafe    exquisitely    intends    biomarkers    sensitive    invasive    sequence    confirming    healthcare    play    strategy    free    genotyping    applicability    laboratory    clinical    whereas    revolutionary    overwhelming    cancer    ctdna    gene    model    validate    advantages    validating    sensitivity    dna    performance    improvement    time    patient    trade    detection    chromosomal    samples    superiority    circulating    proprietary    diagnostics    biopsies    significantly    diagnostic    feasibility    dx    pending    technically    rna    meet    kits    fluids    form    kroma    saga    turn    quantification    through    days    global    body    mutations    road    faster    ready    exact    commercialize    opportunity    disrupt    primary    market    monitoring    liquid    verified    cell    fold    magazine    business    biopsy    weeks    competing    services    rearrangements    forbes    sales    minimally    advantage    revenue    validation    map    superior    patent    continued    isolation    clinically    technologies    variants    competitors    5000    2020    tumour   

Project "EXACT-dna" data sheet

The following table provides information about the project.

Coordinator
SAGA DIAGNOSTICS AB 

Organization address
address: SCHEELEVAGEN 2, MV-401
city: LUND
postcode: 223 81
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://sagadiagnostics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SAGA DIAGNOSTICS AB SE (LUND) coordinator 50˙000.00

Map

 Project objective

Through the EXACT-dna project, SAGA Diagnostics (SAGA Dx), intends to clinically validate and commercialize two distinct technologies, IBSAFE and KROMA, for the isolation, detection and quantification of cell-free circulating tumour DNA (ctDNA) in minimally invasive “liquid biopsies”. This revolutionary form of tumour genotyping and patient monitoring, based on the analysis of ctDNA and other tumour-specific biomarkers in body fluids such as blood samples, is one of five technologies that will disrupt healthcare by 2020 according to Forbes Magazine. SAGA Dx intends to take advantage of this business opportunity by further clinically validating their proprietary technologies which already have overwhelming superiority over competing methods due to four commercially- and technically-verified advantages that meet users’ needs: superior performance (a 100 to 5000-fold improvement in sensitivity), a faster turn-around time of 2-3 days (whereas competitors take 2-3 weeks), significantly lower production costs and wide applicability.

IBSAFE™ is a patent-pending technology for exquisitely sensitive and specific quantification of gene mutations and other sequence variants in any DNA or RNA sample. KROMA™, on the other hand, is a proprietary technology for the detection and quantification of tumour-specific chromosomal rearrangements in circulating tumour DNA.

SAGA Dx’s business model is based on generating revenue from the sales of laboratory services and ready-for-use diagnostic kits which are the primary focus of the Phase 2 project. The Phase 1 project will support this strategy by confirming the market feasibility of our technologies and define a road map for their continued clinical validation. The EXACT –dna project will play a significant role in strengthening the European presence in the rapidly growing global cancer liquid biopsy market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXACT-DNA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXACT-DNA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More  

SINUSLIGHT (2018)

Laser-spectroscopic sensing device for diagnostic assessment of sinusitis

Read More